Study of Single-dose DS-3201b in Participants With Hepatic Impairment
Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, parallel design, single-dose pharmacokinetic (PK) study to
assess the safety, tolerability, and PK of a single dose of 50 mg of DS-3201b in participants
with normal and impaired hepatic function.